Fanconi anaemia is an autosomal recessive disease characterized by chromosome fragility, multiple congenital abnormalities, progressive bone marrow failure and a high predisposition to develop malignancies. Most of the Fanconi anaemia patients belong to complementation group FA-A due to mutations in the FANCA gene. This gene contains 43 exons along a 4.3-kb coding sequence with a very heterogeneous mutational spectrum that makes the mutation screening of FANCA a difficult task. In addition, as the FANCA gene is rich in Alu sequences, it was reported that Alu-mediated recombination led to large intragenic deletions that cannot be detected in heterozygous state by conventional PCR, SSCP analysis, or DNA sequencing. To overcome this problem, a method based on quantitative fluorescent multiplex PCR was proposed to detect intragenic deletions in FANCA involving the most frequently deleted exons (exons 5, 11, 17, 21 and 31). Here we apply the proposed method to detect intragenic deletions in 25 Spanish FA-A patients previously assigned to complementation group FA-A by FANCA cDNA retroviral transduction. A total of eight heterozygous deletions involving from one to more than 26 exons were detected. Thus, one third of the patients carried a large intragenic deletion that would have not been detected by conventional methods. These results are in agreement with previously published data and indicate that large intragenic deletions are one of the most frequent mutations leading to Fanconi anaemia. Consequently, this technology should be applied in future studies on FANCA to improve the mutation detection rate.   

1.
Armour JAL, Barton DE, Cockburn DJ, Taylor GR: The detection of large deletions or duplications in genomic DNA. Hum Mutat 20:325–337 (2002).
2.
Auerbach AD: Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 21:731–733 (1993).
3.
Auerbach AD, Buchwald M, Joenje H: Fanconi Anemia, in Volgestein B, Kinzler KW (eds): The Genetic Basis of Human Cancer, pp 317–332 (McGraw-Hill, New York 1993).
4.
Bogliolo M, Cabré O, Callén E, Castillo V, Creus A, Marcos R, Surrallés J: The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis 17:529–538 (2002).
5.
Casado JA, Callén E, Surrallés J, Segovia JC, Rio P, Lobitz S, Hanenberg H, Bueren JA: Progress in the subtyping analysis of Fanconi anemia patients from Spain using retroviral mediated gene transfer of FA genes and FANCD2 Western blot analysis. Abstract. Twelfth Annual Fanconi Anemia Scientific Symposium, Philadelphia (2002).
6.
Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M: Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 20:218–226 (2002).
7.
Centra M, Memeo E, d’Apolito M, Savino M, Ianzano L, Notarangelo A, Liu J, Doggett NA, Zelante L, Savoia A: Fine exon-intron structure of the Fanconi anemia group A (FAA) gene and characterization of two genomic deletions. Genomics 51:463–467 (1998).
8.
Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher JM, Saurin J, Puisieux A, Olschwang S, Frebourg T: Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 60:2760–2763 (2000).
9.
Fanconi Anemia/ Breast Cancer Consortium: Positional cloning of the Fanconi anemia group A gene. Nature Genet 14:324–328 (1996).
10.
García-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D’Andrea AD: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249–262 (2001).
11.
Hanenberg H, Batish SD, Pollok KE, Vieten L, Verlander PC, Leurs C, Cooper RJ, Gottsche K, Haneline L, Clapp DW, Lobitz S, Williams DA, Auerbach AD: Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol 30:410–420 (2002).
12.
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, de Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D’Andrea AD: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609 (2002).
13.
Ianzano L, D’Apolito M, Centra M, Savino M, Levran O, Auerbach AD, Cleton-Jansen AM, Doggett NA, Pronk JC, Tipping AJ, Gibson RA, Mathew CG, Whitmore SA, Apostolou S, Callen DF, Zelante L, Savoia A: The genomic organization of the Fanconi anemia group A (FAA) gene. Genomics 41:309–314 (1997).
14.
Joenje H, Lo Ten Foe JR, Oostra AB, van Berkel CG, Rooimans MA, Schroeder-Kurth T, Wegner RD, Gille JJ, Buchwald M, Arwert F: Classification of Fanconi anemia patients by complementation analisis: evidence for a fifth genetic subtype. Blood 86:2156–2160 (1995).
15.
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H, Auerbach AD: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249–1256 (2003).
16.
Levran O, Erlich T, Magdalena N, Gregory JJ, Batish SD, Verlander PC, Auerbach AD: Sequence variation in the Fanconi anemia gene FAA. Proc natl Acad Sci, USA 94:13051–13056 (1997).
17.
Levran O, Doggett NA, Auerbach AD: Identification of Alu-mediated deletions in the Fanconi anemia gene FAA. Hum Mutat 12:145–152 (1998).
18.
Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DF, Savoia A, Cheng NC, van Berkel CG, Strunk MH, Gille JJ, Pals G, Kruyt FA, Pronk JC, Arwert F, Buchwald M, Joenje H: Expression cloning of a cDNA for the major Fanconi anemia gene, FAA. Nature Genet 14:320–323 (1996).
19.
Medhurst AL, Huber PA, Waisfisz Q, de Winter JP, Mathew CG: Direct interactions of the five known Fanconi anemia proteins suggest a common functional pathway. Hum molec Genet 10:423–429 (2001).
20.
Morgan NV, Tipping AJ, Joenje H, Mathew CG: High frequency of large intragenic deletions in the Fanconi anemia group A gene. Am J hum Genet 65:1330–1341 (1999).
21.
Savino M, Ianzano L, Strippoli P, Ramenghi U, Arslanian A, Bagnara GP, Joenje H, Zelante L, Savoia A: Mutations of the Fanconi anemia group A gene (FAA) in Italian patients. Am J hum Genet 61:1246–1253 (1997).
22.
Strathdee CA, Duncan AM, Buchwald M: Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9. Nature Genet 1:196–198 (1992).
23.
Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D’Andrea AD: S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100:2414–2420 (2002).
24.
Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, Thayer M, Cox B, Olson S, D’Andrea AD, Moses R, Grompe M: Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 7:241–248 (2001).
25.
Tipping AJ, Pearson T, Morgan NV, Gibson RA, Kuyt LP, Havenga C, Gluckman E, Joenje H, de Ravel T, Jansen S, Mathew CG: Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc natl Acad Sci, USA 98:5734–5739 (2001).
26.
Wang Y, Friedl W, Sengteller M, Jungck M, Filges I, Propping P, Mangold E: A modified multiplex PCR assay for detection of large deletions in MSH2 and MSH1. Hum Mutat 19:279–286 (2002).
27.
Wang Y, Friedl W, Lamberti C, Jungck M, Mathiak M, Pagenstecher C, Propping P, Mangold E: Hereditary nonpolyposis colorectal cancer: Frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 103:636–641 (2003).
28.
Wijker M, Morgan NV, Herterich S, van Berkel CG, Tipping AJ, Gross HJ, Gille JJ, Pals G, Savino M, Altay C, Mohan S, Dokal I, Cavenagh J, Marsh J, van Weel M, Ortega JJ, Schuler D, Samochatova E, Karwacki M, Bekassy AN, Abecasis M, Ebell W, Kwee ML, de Ravel T, Mathew CG: Heterogenous spectrum of mutations in the Fanconi anaemia group A gene. Eur J hum Genet 7:52–59 (1999).
29.
de Winter JP, Waisfisz Q, Rooimans MA, van Berkel CGM, Bosnoyan-Collins L, Alon N, Bender O, Demuth I, Schindler D, Pronk JC, Arwert F, Hoehn H, Digweed M, Buchwald M, Joenje H: The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nature Genet 20:281–283 (1998).
30.
de Winter JP, Leveille F, Waisfisz Q, van Berkel CG, Rooimans MA, van Der Weel L, Steltenpool J, Demuth I, Morgan NV, Alon N, Bosnoyan-Collins L, Lightfoot J, Leegwater PA, Waisfisz Q, Komatsu K, Arwert F, Pronk JC, Mathew CG, Digweed M, Buchwald M, Joenje H: Isolation of a cDNA representing the Fanconi anemia complementation goup E gene. Am J hum Genet 67:1306–1308 (2000a).
31.
de Winter JP, Rooimans MA, van Der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y, Waisfisz Q, Pronk JC, Arwert F, Mathew CG, Scheper RJ, Hoatlin ME, Buchwald M, Joenje H: The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nature Genet 24:15–16 (2000b).
32.
de Winter JP, van der Weel L, de Groot J, Stone S, Waisfisz Q, Arwert F, Scheper RJ, Kruyt FA, Hoatlin ME, Joenje H: The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum molec Genet 9:2665–2674 (2000c).
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.